LOX and breast cancer: Hence, the results of the radiopharmacological investigations of the radiolabelled DPK peptide [18F]31a in the three different murine breast cancer models suggest that this radiotracer is subject to tumour accumulation which is partially mediated by lysyl oxidases, to a similar extent as in the A375-derived melanoma model.[116] This conclusion encourages the design of radiotracers based on irreversible inhibitors derived from compound 31a in order to enhance target rentention and, consequently, image contrast of the probe.